Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.
Abstract
Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.
참고문헌 (27)
- Andre F, "Hepatitis B epidemiology in Asia,the Middle East and Africa", 18, pp.S20~S22 (2000)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2005 update", 25, pp.472~489 (2005)
- Lok AS, "Chronic hepatitis B: update of recommendations", 39, pp.857~861 (2004)
- Hoofnagle JH, "Reactivation of chronic hepatitis B virus infection by cancer chemotherapy", 96, pp.447~9 (1982)
- Vento S, "Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy:an unresolved issue", 3, pp.333~340 (2002)
- Ohtsu T, "Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies", 21, pp.360~5 (1991)
- Xunrong L, "Hepatitis B virus(HBV)reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management", 11, pp.287~299 (2001)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors", 62, pp.299~307 (2000)
- Cheng AL, "Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV- carriers with lymphoma", 37, pp.1320~1328 (2003)
- Leaw SJ, "Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy", 83, pp.270~275 (2004)
- Simpson ND, "Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine", 37, pp.68~71 (2003)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", 351, pp.1521~1531 (2004)
- Idilman R, "Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy", 55, pp.828~831 (2005)
- Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", 125, pp.1742~1749 (2003)
- Yeo W, "Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients", 88, pp.209~215 (2004)
- Yeo W, "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy", 22, pp.927~934 (2004)
- Rossi G, "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy", 115, pp.58~62 (2001)
- Shibolet O, "Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers", 100, pp.391~396 (2002)
- Song BC, "Hepatitis B virus genotypes in Korea:an endemic area of hepatitis B virus infection", 48, pp.133~137 (2005)
- Zhong S, "High hepatitis B virus(HBV)DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy", 11, pp.55~59 (2004)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors", 62, pp.299~307 (2000)
- Tsutsumi Y, "Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab:necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy", 45, pp.627~629 (2004)
- Tsutsumi Y, "Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma", 83, pp.58~60 (2004)
- Ma SY, "Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation", 44, pp.1281~1285 (2003)
- Hui CK, "Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy", 54, pp.1597~1603 (2005)
- Song BC, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", 32, pp.803~806 (2000)
- "Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea", 35, pp.92~98 (2001)